APA (7th ed.) Citation

Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, . . . Hongyan Shang. (2023). Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Elsevier.

Chicago Style (17th ed.) Citation

Binghe Xu, et al. Entinostat, a Class I Selective Histone Deacetylase Inhibitor, Plus Exemestane for Chinese Patients with Hormone Receptor-positive Advanced Breast Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial. Elsevier, 2023.

MLA (9th ed.) Citation

Binghe Xu, et al. Entinostat, a Class I Selective Histone Deacetylase Inhibitor, Plus Exemestane for Chinese Patients with Hormone Receptor-positive Advanced Breast Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial. Elsevier, 2023.